Rochester, NY 8/25/2009 7:25:24 PM
Sanofi-Aventis SA; SNY, Sanofi-Aventis barks for local anti-rabies brand
Sanofi-Aventis SA; SNY
Aventis Pharma Ltd known drug maker, the Indian-listed subsidiary of French pharma company Sanofi-Aventis SA, is in talks to acquire local rabies vaccine brands after flagship product Rabipur losses it marketing rights in a market estimated to be worth an annual Rs300 crore.
The company is promoting as well a clutch of research-based drug companies in India for licensing potential technologies for products that can compensate it for the lost market slot, said two people involved in the negotiations who did not want to be named.Also, Sanofi-Aventis explores the option of terminating a marketing agreement with Ranbaxy Laboratories Ltd for Verorab, another local rabies vaccine brand that belongs to group company Sanofi Pasteur SA, and launching it directly in the Indian market, said the two people. Spokesperson of Sanofi-Aventis said the company still targets of looking for brands in the anti-rabies aspect to compensate for the Rabipur loss.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
